Insilico Medicine

Last updated

Insilico Medicine
Company typePrivate
Industry Biotechnology
Founded2014 (2014) [1]
Founder Alex Zhavoronkov
Headquarters1000 Massachusetts Avenue,
Boston; [2]
Number of locations
6
Area served
 Artificial intelligence, deep learning
Key people
Alex Zhavoronkov, PhD, Feng Ren, PhD, Alex Aliper, PhD, Michelle Chen, PhD, Nirav Jhaveri, MBA, Quentin Vanhaelen, PhD
ServicesDrug discovery
Website insilico.com

Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, [2] with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, [3] and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery. [4] [5] [6]

Contents

History

In 2011, Alex Zhavoronkov published an article in the journal PLOS One with Dr. Charles Cantor, previously director of the Human Genome Project at the Department of Energy (DOE) and founder of Sequenom on the International Aging Research Portfolio (IARP), establishing a public data set tracking government research funding and outcomes. [7] This work formed the basis for an artificial intelligence (AI) pharmacological analysis platform.

Zhavoronkov assertedly founded Insilico Medicine in 2014, as an alternative to animal testing for research and development programs in the pharmaceutical industry, using AI and deep-learning techniques to analyze how a compound will affect cells and what drugs can be used to treat the cells in addition to possible side effects. Through its Pharma.AI division, the company provides machine learning services to different pharmaceutical, biotechnology, and skin care companies. [8] [9] Insilico is known for hiring mainly through hackathons such as their own MolHack online hackathon. [10]

The company has multiple collaborations in the applications of next-generation artificial intelligence technologies such as the generative adversarial networks (GANs) and reinforcement learning to the generation of novel molecular structures with desired properties. [11] [12] In 2016, Insilico published an algorithm that it called the "Insilico Pathway Activation Network Decomposition Analysis" or "iPANDA" algorithm, asserted to allow researchers "to quickly and efficiently analyze signaling and metabolic pathway perturbation states using gene expression data". [13] In conjunction with Alan Aspuru-Guzik's group at Harvard, they published a journal article about an improved GAN architecture for molecular generation which combines GANs, reinforcement learning, and a differentiable neural computer. [14]

In 2017, Insilico was named one of the Top five AI companies by NVIDIA for its potential for social impact. [15] Insilico has R&D resources in Belgium, Russia, and the UK and hires talent through hackathons and other local competitions. [16] By mid-2017, Insilico had raised $8.26 million in funding from investors including Deep Knowledge Ventures, JHU A-Level Capital, [17] Jim Mellon, [18] and Juvenescence. [1] [19] [20] [21] In 2019 it raised another $37 million from Fidelity Investments, Eight Roads Ventures, Qiming Venture Partners, WuXi AppTec, Baidu, Sinovation, Lilly Asia Ventures, Pavilion Capital, BOLD Capital, and other investors. [22]

The company "focused exclusively on drug discovery until 2019 when it began developing its own therapeutics". [23] In January 2021, Insilico entered into a partnership with Fosun Pharma, to facilitate entry into the Chinese market. [23] Later in 2021 after developing a novel preclinical candidate molecule for a novel target, [24] the company announced a series C $255 million megaround [25] from Warburg Pincus, Sequoia Capital, Orbimed, Mirae Asset Financial Group, and over 25 biotechnology, AI, and pharmaceutical investors. [26] [27] By mid-2021, it claimed to have nominated eight preclinical candidates. [23] Another $60 million in new Series D financing was raised in 2022. [23] As of 2023 it was reported that over $400 million had been invested in the company. [28] In 2023, Zhavoronkov stated that he "moved the company's R&D to China to capitalize on 'half a trillion dollars' worth of infrastructure and hundreds of thousands of scientists [provided by the government] to enable AI-designed drugs". [29] In mid-2024, it was reported that the corporate headquarters had relocated to Boston, Massachusetts. [2] In November 2024, Insilico was named one of the top 50 AI innovators by Fortune magazine. [30]

Research

The company "applies DL, big data, and genomis for in silico drug discovery" for various conditions. [3] It has sought to develop AI to "identify novel drug targets for untreated diseases", and has pursued dual-purpose therapeutics, "going after a specific disease or several diseases while targeting ageing at the same time". [28]

In 2019, the company in partnership with researchers at the University of Toronto, used AI to design potential new drugs. One was reported to have shown promising initial results when tested in mice. [31] [32] Research areas for therapeutics have included fibrosis, immunology, oncology and the central nervous system. [23] To demonstrate the capacity of their proprietary AI platforms, the company published two projects on identifying therapeutic targets for ageing [33] and amyotrophic lateral sclerosis [34] in 29 March and 28 June 2022, respectively.[ citation needed ]

The company has collaborated with scientists at the University of Chicago, George Mason University, and University of Liverpool, focusing on ageing. [35] For ALS, the company worked with researchers from Answer ALS, Johns Hopkins University School of Medicine, Harvard Medical School, Mayo Clinic, Tsinghua University, and 4B Technologies Limited. [36] In 2023, it was reported that Insilico had initiated "one of the first mid-stage human trials of a drug discovered and designed by artificial intelligence". [37] [38]

Outside of human drugs, in 2021 the company partnered with Swiss company Syngenta weedkillers. [39]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">AstraZeneca</span> British-Swedish pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Christoph Westphal is an American biomedical businessman.

Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

<span class="mw-page-title-main">Evotec</span> German biopharmaceutical company

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.

SynBio is a long-term project started in 2011 with the goal of creating innovative medicines, including what are known as Biobetters. This project is a collaborative effort of several Russian and international pharmaceutical companies. The largest private participant of SynBio is the Human Stem Cells Institute (HSCI), a leading Russian biotech company, and Rusnano is a key investor. The project is a significant example of international cooperation between researchers in Russia, England, and Germany. Special project company SynBio LLC is headquartered in Moscow.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">SOM Biotech</span>

SOM Innovation Biotech, S.A., is a private pharmaceutical company focused on the accelerated discovery and development of therapies for orphan diseases through a proprietary artificial intelligence-based drug discovery technology and developing strategic partnerships with major research centers and pharmaceutical companies. The company was founded in 2009 in Barcelona, Spain.

<span class="mw-page-title-main">OS Fund</span> American venture-capital fund

OS Fund is an American venture capital fund that invests in early-stage science and technology companies.

<span class="mw-page-title-main">Scientist.com (company)</span> Network of e-commerce marketplaces

Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services. The company was founded in 2007 by Kevin Lustig, Chris Petersen and Andrew Martin and launched its first public research marketplace in September 2008.

Verseon International Corporation is a clinical-stage pharmaceutical company based in Fremont, California. It is developing several drug discovery programs in cardiometabolic diseases and cancer featuring drug candidates that represent novel chemical matter designed using molecular physics and artificial intelligence.

VITAL was a Board Management Software machine learning proprietary software developed by Aging Analytics, a company registered in Bristol (England) and dissolved in 2017. Andrew Garazha declared that the project aimed "through iterative releases and updates to create a piece of software capable of making autonomous investment decisions." According to Nick Dyer-Witheford, VITAL 1.0 was a "basic algorithm".

Owkin is an AI biotech company that uses artificial intelligence to identify new treatments, optimize clinical trials and develop AI diagnostics. The company uses federated learning, a type of privacy preserving technology, to access multimodal patient data from academic institutions and hospitals to train its AI models for drug discovery, development, and diagnostics. Owkin has collaborated with pharmaceutical companies around the world to improve their therapeutic programs.

<span class="mw-page-title-main">Alex Zhavoronkov</span> Latvian-born AI and longevity researcher

Alex Zhavoronkov is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine, and as of 2024, was also the director of the Biogerontology Research Foundation, a UK-based think-tank for aging research. Zhavoronkov has published a substantial number of papers, and books including The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy.

<span class="mw-page-title-main">AION Labs</span>

AION Labs is an Israeli venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering.

References

  1. 1 2 Gantz S (23 February 2017). "Insilico Medicine raises $10 million". The Baltimore Sun. Tribune Publishing. Retrieved 16 July 2020.
  2. 1 2 3 Philippidis, Alex (20 June 2024). "Insilico Moves HQ to Cambridge, MA, Completes IPF Trial Enrollment". GEN - Genetic Engineering and Biotechnology News.
  3. 1 2 Saharan, Vikas Anand (2022). Computer Aided Pharmaceutics and Drug Delivery. Springer. p. 363-64.
  4. ↑ "Insilico Medicine launches a drug discovery platform ALS.AI". EurekAlert!. 1 June 2017. Retrieved 28 August 2017.
  5. ↑ Al Idrus A (16 August 2017). "GlaxoSmithKline taps Baltimore's Insilico for AI-based drug discovery". FierceBiotech. Retrieved 28 August 2017.
  6. ↑ "InSilico Medicine Company Profile". PitchBook. Retrieved 28 August 2017.
  7. ↑ Zhavoronkov A, Cantor CR (2011). "Methods for structuring scientific knowledge from many areas related to aging research". PLoS One. 6 (7): e22597. doi: 10.1371/journal.pone.0022597 . PMC   3142169 . PMID   21799912.
  8. ↑ "New partnership uses artificial intelligence methods to develop solutions for preventing early aging". News-Medical.net. 1 August 2017. Retrieved 28 August 2017.
  9. ↑ Sandle T (12 August 2017). "Can artificial intelligence aid human age-reversal?". Archived from the original on 14 August 2017. Retrieved 28 August 2017.
  10. ↑ "MolHack Hackathon". molhack.com. Retrieved 10 August 2018.
  11. ↑ Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A (September 2017). "druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico". Molecular Pharmaceutics. 14 (9): 3098–3104. doi:10.1021/acs.molpharmaceut.7b00346. PMID   28703000.
  12. ↑ Cox P (14 March 2017). "Here's How Pharma Is Using AI Deep Learning To Cure Aging". Forbes. Retrieved 12 September 2017.
  13. ↑ "From Paper to Industrial-scale Platform: a 7-year Behind the Paper Journey from iPANDA to PandaOmics AI-Powered Target Discovery Platform". Nature Portfolio Bioengineering Community. 13 September 2022.
  14. ↑ Putin E, Asadulaev A, Ivanenkov Y, Aladinskiy V, Sanchez-Lengeling B, Aspuru-Guzik A, Zhavoronkov A (June 2018). "Reinforced Adversarial Neural Computer for de Novo Molecular Design". Journal of Chemical Information and Modeling. 58 (6): 1194–1204. doi: 10.1021/acs.jcim.7b00690 . PMID   29762023.
  15. ↑ Takahashi D (23 April 2017). "Nvidia identifies the top 5 AI startups for social impact". VentureBeat. Retrieved 28 August 2017.
  16. ↑ "AgeHack@MLBootCamp: The first Eurasian hackathon on AI for longevity to launch". 13 June 2017. Retrieved 28 August 2017.
  17. ↑ "JHU alumni-run A-Level Capital to support AI-powered drug discovery at Insilico Medicine". EurekAlert!. 28 June 2017. Retrieved 12 September 2017.
  18. ↑ McConaghie A (11 April 2017). "Billionaire Jim Mellon invests in anti-ageing research firm - Pharmaphorum". Pharmaphorum. Retrieved 12 September 2017.
  19. ↑ Galeon D (2 August 2017). "AI Is Helping This Anti-Aging Startup Uncover Ways for You to Live a Longer, Healthier Life". Futurism. Retrieved 12 September 2017.
  20. ↑ Fassbender M (August 2017). "Insilico, Juvenescence joint venture to develop AI-discovered molecules into new drugs". Outsourcing-Pharma.com. Retrieved 28 August 2017.
  21. ↑ Babcock S (28 July 2017). "Insilico Medicine signs deal to advance use of AI in discovering new drugs". Technical.ly. Baltimore. Retrieved 28 August 2017.
  22. ↑ Hale C (14 April 2021). "Insilico raises $37M with plans to bring its AI to more drug discovery partnerships". Fierce Biotech. Retrieved 14 April 2021.
  23. 1 2 3 4 5 Liao, Rita (6 June 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch .
  24. ↑ Hale C (22 February 2021). "Breaking Big Pharma's AI barrier: Insilico Medicine uncovers novel target, new drug for pulmonary fibrosis in 18 months". Fierce Biotech. Retrieved 23 July 2021.
  25. ↑ Gelman M (22 June 2021). "With a new $255M megaround in hand, Alex Zhavoronkov has big plans for Insilico. Are they feasible?". Endpoints. Retrieved 23 July 2021.
  26. ↑ Betuel E (22 June 2021). "AI drug discovery platform Insilico Medicine announces $255 million in Series C funding". Techcrunch. San Francisco. Retrieved 23 July 2021.
  27. ↑ "AI drug discovery start-up Insilico raises more than $255m". Financial Times. London. 22 June 2021. Retrieved 23 July 2021.
  28. 1 2 Tan, Dawn; Baker, Jalelah Abu (4 January 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
  29. ↑ Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (2 April 2023), p. K1, K5.
  30. ↑ Estrada, Sheryl (21 November 2024). "From Nvidia to Anthropic, meet the Fortune 50 AI Innovators". Fortune.
  31. ↑ Jee C (3 September 2019). "An AI system identified a potential new drug in just 46 days". MIT Technology Review. Retrieved 14 August 2020.
  32. ↑ Knapp A. "This Startup Used AI To Design A Drug In 21 Days". Forbes. Retrieved 14 August 2020.
  33. ↑ Pun FW, Leung GH, Leung HW, Liu BH, Long X, Ozerov IV, et al. (March 2022). "Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine". Aging. 14 (6): 2475–2506. doi:10.18632/aging.203960. PMC   9004567 . PMID   35347083.
  34. ↑ Pun FW, Liu BH, Long X, Leung HW, Leung GH, Mewborne QT, et al. (28 June 2022). "Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform". Frontiers in Aging Neuroscience. 14: 914017. doi: 10.3389/fnagi.2022.914017 . PMC   9273868 . PMID   35837482.
  35. ↑ Sabry, Fouad (2022). Senolytic: Selectively induce death of senescent cells to improve humans' health. One Billion Knowledgeable. p. 93.
  36. ↑ Sarkar, Anjali A. (7 July 2022). "AI Finds Potential Drug Targets for Amyotrophic Lateral Sclerosis". GEN - Genetic Engineering and Biotechnology News.
  37. ↑ Smyth, Jamie (26 June 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times .
  38. ↑ Rosso, Cami (25 January 2023). "AI Finds Drug Candidate for Liver Cancer in 30 Days". Psychology Today .
  39. ↑ Andrew Noël and Agnieszka de Sousa, "AI is becoming a weapon in the battle against pests", Owensboro Messenger-Inquirer (via Bloomberg News, 7 February 2021), p. A5.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.